Idexx Laboratories (IDXX) Liabilities and Shareholders Equity (2009 - 2026)

Idexx Laboratories' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $3.4 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.35% year-over-year to $3.4 billion; the TTM figure through Mar 2026 stood at $13.5 billion (up 1.36% YoY), while the FY2025 annual figure was $3.4 billion, up 1.74% from the prior year.
• Liabilities and Shareholders Equity was $3.4 billion for Q1 2026 at Idexx Laboratories, up from $3.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.4 billion in Q2 2024 to a low of $2.6 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $3.1 billion across 5 years, with a median of $3.3 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity gained 19.41% in 2024, then declined 4.17% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.7 billion in 2022, then rose by 18.68% to $3.3 billion in 2023, then increased by 1.03% to $3.3 billion in 2024, then advanced by 1.74% to $3.4 billion in 2025, then grew by 1.04% to $3.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $3.4 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.4 billion (Q3 2025), per Business Quant data.